{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:27:19Z","timestamp":1787430439355,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbadis.2026.168342","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:35:49Z","timestamp":1782923749000},"page":"168342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A proliferation-inducing ligand enhances the anti-tumor effect of BCMA CAR T-cell through inhibition of soluble BCMA"],"prefix":"10.1016","volume":"1872","author":[{"given":"Huanhuan","family":"She","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bbadis.2026.168342_bb0005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168342_bb0010","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.bbadis.2026.168342_bb0015","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bbadis.2026.168342_bb0020","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"issue":"20","key":"10.1016\/j.bbadis.2026.168342_bb0025","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168342_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.bbadis.2026.168342_bb0035","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41587-024-02339-4","article-title":"A CAR enhancer increases the activity and persistence of CAR T cells","volume":"43","author":"Rakhshandehroo","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168342_bb0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168342_bb0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","article-title":"The BAFF\/APRIL system in SLE pathogenesis","volume":"10","author":"Vincent","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"issue":"734","key":"10.1016\/j.bbadis.2026.168342_bb0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg7962","article-title":"Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo","volume":"16","author":"Diez-Alonso","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168342_bb0055","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.bbadis.2026.168342_bb0060","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bbadis.2026.168342_bb0065","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood.2024024965","article-title":"Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes","volume":"145","author":"Freeman","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bbadis.2026.168342_bb0070","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"Gamma-secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.bbadis.2026.168342_bb0075","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1158\/0008-5472.CAN-14-0079","article-title":"Efficacy of CAR T-cell therapy in large tumors relies upon stromal targeting by IFNgamma","volume":"74","author":"Textor","year":"2014","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbadis.2026.168342_bb0080","first-page":"240","article-title":"Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy","volume":"5","author":"Ghasemi","year":"2024","journal-title":"Nat. Can."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168342_bb0085","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ccell.2025.05.013","article-title":"CSF1R(+) myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma","volume":"43","author":"Stahl","year":"2025","journal-title":"Cancer Cell"},{"issue":"1\u20132","key":"10.1016\/j.bbadis.2026.168342_bb0090","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0022-1759(02)00028-5","article-title":"A comparison of ELISA and flow microsphere-based assays for quantification of immunoglobulins","volume":"263","author":"Dasso","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bbadis.2026.168342_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8333","article-title":"Gamma-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbadis.2026.168342_bb0100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/79802","article-title":"APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity","volume":"1","author":"Yu","year":"2000","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168342_bb0105","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/j.bbadis.2026.168342_bb0110","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/mt.2011.256","article-title":"Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor","volume":"20","author":"Lanitis","year":"2012","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168342_bb0115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/sj.cgt.7700685","article-title":"Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins","volume":"11","author":"Ma","year":"2004","journal-title":"Cancer Gene Ther."},{"issue":"769","key":"10.1016\/j.bbadis.2026.168342_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj9331","article-title":"Human OX40L-CAR-T(regs) target activated antigen-presenting cells and control T cell alloreactivity","volume":"16","author":"Rui","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.bbadis.2026.168342_bb0125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41551-024-01195-6","article-title":"Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression","volume":"8","author":"Sirpilla","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"8","key":"10.1016\/j.bbadis.2026.168342_bb0130","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.bbadis.2026.168342_bb0135","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bbadis.2026.168342_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005091","article-title":"Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization","volume":"10","author":"Camviel","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.bbadis.2026.168342_bb0145","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy - interim analysis of a phase 3 trial","volume":"394","author":"Perkovic","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bbadis.2026.168342_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.bbadis.2026.168342_bb0155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092544392600205X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092544392600205X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:19:33Z","timestamp":1787429973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092544392600205X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S092544392600205X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168342","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A proliferation-inducing ligand enhances the anti-tumor effect of BCMA CAR T-cell through inhibition of soluble BCMA","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2026.168342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"168342"}}